223. 一次性膜性増殖性糸球体腎炎 [臨床試験数:13,薬物数:12(DrugBank:5),標的遺伝子数:10,標的パスウェイ数:38]
Searched query = "Primary membranoproliferative glomerulonephritis", "Dense deposit disease"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/20/2019, 11/21/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT03459443 | June 20, 2018 | 30 September 2019 | A Proof of Concept Study for a 12 Month Treatment in Patients With C3 Glomerulopathy (C3G) or Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN) | An Open-Label Phase 2 Proof-of-Concept Study in Patients With C3 Glomerulopathy (C3G) or Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN) Treated With ACH-0144471 | C3 Glomerulonephritis;C3 Glomerulopathy;Immune Complex Membranoproliferative Glomerulonephritis;IC-MPGN;Dense Deposit Disease | Drug: ACH-0144471 | Achillion Pharmaceuticals | Not recruiting | 17 Years | 65 Years | All | 22 | Phase 2 | United States;Australia;Belgium;Italy;Netherlands | |
2 | NCT03369236 | June 12, 2018 | 2 September 2019 | A Proof of Concept Study for 6 Month Treatment in Patients With C3 Glomerulopathy (C3G) | A Phase 2, Proof-of-Concept, Randomized, Double-Blinded, Placebo-Controlled Study of ACH-0144471 Treatment for 6 Months in Patients With C3 Glomerulopathy (C3G) | C3 Glomerulopathy;C3 Glomerulonephritis;Dense Deposit Disease | Drug: ACH-0144471;Drug: Placebo | Achillion Pharmaceuticals | Not recruiting | 17 Years | 65 Years | All | 13 | Phase 2 | United States;United Kingdom | |
3 | NCT03453619 | January 22, 2018 | 28 January 2019 | Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies | A Phase 2 Study to Evaluate the Safety and Biologic Activity of APL- 2 in Patients With IgA Nephropathy, Lupus Nephritis, Primary Membranous Nephropathy, or C3 Glomerulopathy (C3 Glomerulonephritis and Dense Deposit Disease) | IgA Nephropathy;Lupus Nephritis;Membranous Nephropathy;C3 Glomerulonephritis;Dense Deposit Disease | Drug: APL-2 | Apellis Pharmaceuticals, Inc. | Recruiting | 18 Years | N/A | All | 48 | Phase 2 | United States | |
4 | EUCTR2017-001821-42-BE | 15/01/2018 | 28 February 2019 | A Clinical Trial to Evaluate the Safety and Efficacy of CCX168 (Avacopan), a new drug for the treatment of a group of related conditions that cause the kidneys to malfunction, called C3 Glomerulopathy. | A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Safety and Efficacy of Avacopan (CCX168) in Patients with C3 Glomerulopathy | C3 glomerulopathy (C3G) is characterized by evidence of alternative complement activation based on C3 deposition in the glomeruli. There are two forms of the disease: dense deposit disease (DDD, formerly called membranoproliferative glomerulonephritis [MPGN] Type II) and C3 glomerulonephritis (C3GN, formerly called idiopathic MPGN). MedDRA version: 20.0 Level: PT Classification code 10077827 Term: C3 glomerulopathy System Organ Class: 10038359 - Renal and urinary disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: Avacopan Product Code: CCX168 Pharmaceutical Form: Capsule INN or Proposed INN: AVACOPAN CAS Number: 1346623-17-3 Current Sponsor code: CCX168 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use | ChemoCentryx, Inc. | Authorised | Female: yes Male: yes | 88 | Phase 2 | France;United States;Canada;Spain;Belgium;Ireland;Denmark;Netherlands;Germany;Italy;United Kingdom | |||
5 | NCT03124368 | August 9, 2017 | 11 November 2019 | A Proof-of-Mechanism Study to Determine the Effect of ACH-0144471 on C3 Levels in Patients With C3G or IC-MPGN | A Phase 2a Proof-of-Mechanism, Open-Label Study to Determine the Effect of ACH-0144471 on C3 Levels in Patients With Low C3 Levels Due to Either C3 Glomerulopathy (C3G) or Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN) | C3 Glomerulonephritis;Dense Deposit Disease;Membranoproliferative Glomerulonephritis, Type II;C3 Glomerulopathy;Immune Complex Mediated Membranoproliferative Glomerulonephritis | Drug: ACH-0144471 | Achillion Pharmaceuticals | Not recruiting | 16 Years | 65 Years | All | 6 | Phase 2 | Australia;Belgium;Netherlands | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
6 | NCT03180723 | July 1, 2017 | 16 December 2017 | Effect of Rituximab in Treatment of Membranoproliferative Glomerulonephritis | Effect of Rituximab in Treatment of Primary Membranoproliferative Glomerulonephritis | Membranoproliferative Glomerulonephritis | Drug: Rituximab;Drug: Cyclosporin | Assiut University | Not recruiting | 18 Years | N/A | All | 30 | Phase 3 | ||
7 | NCT02682407 | February 2016 | 22 January 2018 | Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721 | A Phase 2 Study to Evaluate the Safety and Effect on Proteinuria of OMS721 in Subjects With IgA Nephropathy, Lupus Nephritis, Membranous Nephropathy, or C3 Glomerulopathy Including Dense Deposit Disease | IgAN;Lupus Nephritis;MN;C3G | Biological: OMS721;Other: Vehicle (D5W) | Omeros Corporation | Recruiting | 18 Years | N/A | All | 44 | Phase 2 | United States | |
8 | NCT02302755 | November 2014 | 7 November 2016 | TP10 Use in Patients With C3 Glomerulopathy (C3G) | A Pilot, Open-Label Single Center Trial of TP10 in Pediatric and Adult Patients With C3 Glomerulopathy (C3G) | Dense Deposit Disease | Drug: TP10 | University of Iowa | Not recruiting | 4 Years | N/A | Both | 0 | Phase 1 | United States | |
9 | NCT02093533 | March 2014 | 29 January 2018 | Eculizumab in Primary MPGN | EVALUATING THE MORPHOFUNCTIONAL EFFECTS OF ECULIZUMAB THERAPY IN PRIMARY MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS: A PILOT, SINGLE ARM STUDY IN TEN PATIENTS WITH PERSISTENT HEAVY PROTEINURIA | Membranoproliferative Glomerulonephritis | Drug: Eculizumab | Mario Negri Institute for Pharmacological Research | Alexion Pharma Italy s.r.l. | Not recruiting | N/A | 75 Years | All | 10 | Phase 2 | Italy |
10 | EUCTR2013-003826-10-IT | 24/01/2014 | 19 February 2018 | ECULIZUMAB THERAPY IN PRIMARY MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS | EVALUATING THE MORPHOFUNCTIONAL EFFECTS OF ECULIZUMAB THERAPY IN PRIMARY MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS: A PILOT, SINGLE ARM STUDY IN TEN PATIENTS WITH PERSISTENT HEAVY PROTEINURIA - Eculizumab in primary MPGN | Membranoproliferative glomerulonephritis;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Trade Name: Soliris Product Name: Soliris Pharmaceutical Form: Concentrate for solution for injection/infusion INN or Proposed INN: ECULIZUMAB CAS Number: 219685-50-4 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 300- | IRCCS- Mario Negri Institute | Not Recruiting | Female: yes Male: yes | 10 | Phase 2 | Italy | |||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
11 | NCT01791686 | January 2013 | 19 February 2015 | Clinical Trial of CDX-1135 in Pediatric and Adult Patients With Dense Deposit Disease | A Pilot, Open-label, Multicenter Clinical Trial of CDX-1135 in Pediatric and Adult Patients With Dense Deposit Disease | Dense Deposit Disease;Membranoproliferative Glomerulonephritis Type II;C3 Glomerulonephritis | Drug: CDX-1135 | Celldex Therapeutics | Not recruiting | 4 Years | N/A | Both | 1 | Phase 1 | United States | |
12 | NCT01221181 | July 2010 | 4 March 2019 | Eculizumab Therapy for Dense Deposit Disease and C3 Nephropathy | Eculizumab Therapy for Dense Deposit Disease and C3 Nephropathy | Dense Deposit Disease;Membranoproliferative Glomerulonephritis | Drug: Eculizumab | Columbia University | Alexion Pharmaceuticals | Not recruiting | 18 Years | N/A | All | 6 | Phase 1 | United States |
13 | NCT00583427 | December 2007 | 29 June 2015 | Sulodexide Treatment in Patients With Dense Deposit Disease | Sulodexide Treatment in Patients With Dense Deposit Disease | Dense Deposit Disease | Drug: Sulodexide | University of Iowa | Not recruiting | 5 Years | 20 Years | Both | 0 | Phase 1 | United States |